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Lung cancer is the leading cause of cancer deaths world-
wide [1]. Recently, various therapeutic strategies for lung 
cancer have been developed; however, these strategies are 
not sufficient for overcoming lung cancer. Patients with 
early- stage lung cancer are usually treated by surgical 
resection, which is successful in most cases. On the other 
hand, patients with advanced lung cancer are often treated 
using multimodal therapy, including chemotherapy, radio-
therapy, and surgical resection. Some studies have provided 
promising results for the effects of multimodal therapy; 
however, this therapeutic effectiveness has not been com-
pletely evident [2]. Chemoresistance is an important limi-
tation that hampers the improvement in prognosis of lung 
cancer patients.
Our previous studies have shown that prognosis of 
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Abstract
Lung cancer treatment is difficult owing to chemoresistance. Hypoxia- inducible 
factor 1 (HIF- 1) and HIF- 1- induced glycolysis are correlated with chemoresist-
ance; however, this is not evident in lung cancer. We investigated the effect of 
HIF- 1α and carbonic anhydrase IX (CAIX), a transmembrane protein neutral-
izing intracellular acidosis, on chemoresistance and prognosis of lung cancer 
patients after induction chemoradiotherapy. Associations of HIF- 1α, glucose 
transporter 1 (GLUT1), and CAIX with chemoresistance of lung cancer were 
investigated using A549 lung cancer cells under normoxia or hypoxia in vitro. 
HIF- 1α- induced reprogramming of glucose metabolic pathway in A549 cells 
and the effects of HIF- 1 and CAIX on the cytotoxicity of vinorelbine were 
investigated. Immunohistochemical analyses were performed to determine HIF- 
1α, GLUT1, and CAIX expression levels in cancer specimens from lung cancer 
patients after induction chemoradiotherapy. Hypoxia induced HIF- 1α expression 
in A549 cells. Moreover, hypoxia induced GLUT1 and CAIX expression in A549 
cells in a HIF- 1- dependent manner. Glucose metabolic pathway was shifted 
from oxidative phosphorylation to glycolysis by inducing HIF- 1α in A549 cells. 
HIF- 1 and CAIX induced chemoresistance under hypoxia, and their inhibition 
restored the chemosensitivity of A549 cells. The expression levels of HIF- 1α, 
GLUT1, and CAIX were associated with poor overall survival of lung cancer 
patients after induction chemoradiotherapy. HIF- 1 and CAIX affected the che-
mosensitivity of A549 cells and prognosis of lung cancer patients. Therefore, 
inhibition of HIF- 1 and CAIX might improve prognosis of lung cancer patients 
after induction chemoradiotherapy. Further analysis might be helpful in devel-
oping therapies for lung cancer.
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especially stage IIIA NSCLC patients with mediastinal 
lymph node metastasis, can be improved using multimodal 
therapy [3]. However, cancer progression during chemo-
therapy or relapse after postoperative therapy often occurs 
probably because of the induction of chemoresistance 
through some mechanisms.
Hypoxic microenvironment in a malignant solid tumor 
has been reported to be strongly correlated with cancer 
progression and chemoresistance. Hypoxia- inducible factor 
1 (HIF- 1), which is a heterodimeric transcription factor 
composed of α and β subunit (HIF- 1α and HIF- 1β, 
respectively) and whose activity is mainly dependent on 
the expression levels of the former, is recognized as a key 
factor associated with chemoresistance of lung cancer [4], 
with HIF- 1- induced glycolysis playing an important role 
in promoting this chemoresistance [5].
HIF- 1- induced glycolysis exerts many effects on tumor 
progression and on the mode of energy production [5]. 
A recent study showed associations between glycolysis 
and chemoresistance [6]. Upregulation of glycolysis 
increases glucose uptake through glucose transporter 1 
(GLUT1) [5], a key regulator of glycolysis that has been 
investigated as a diagnostic tool and therapeutic target 
for cancer [7].
Because intracellular acidosis is induced by lactate and 
proton production during glycolysis, the mechanism cop-
ing with intracellular acidosis is essential for the main-
tenance of cellular homeostasis. As a coping mechanism, 
carbonic anhydrase IX (CAIX), a transmembrane protein 
neutralizing intracellular acidosis, is induced by HIF- 1 
and is associated with glycolysis in some cancers [8]. 
Some studies have reported the effects of CAIX on prog-
nosis and chemoresistance of patients with different 
cancers [9]. However, few studies have reported the effects 
of CAIX on prognosis and chemoresistance of lung cancer 
patients.
HIF- 1- induced glycolysis is highly associated with cancer 
progression. Therefore, the investigation of this pathway 
in lung cancer is important for developing novel cancer 
therapies. The purpose of our study is to elucidate the 
effects of HIF- 1α and CAIX on chemoresistance and 
prognosis of lung cancer patients after induction chemo-
radiotherapy, and finally to improve them.
Materials­and­Methods
Cell­culture­and­reagents
Human lung adenocarcinoma cell- line A549 was obtained 
from American Type Culture Collection (Manassas, VA) 
and was cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma- Aldrich, St. Louis, MO) containing 10% 
fetal bovine serum (FBS).
For normoxic experiments, A549 cells were incubated 
in a well- humidified incubator with 5% CO2 and 95% 
air at 37°C. For hypoxic experiments, A549 cells were 
incubated with <0.1% O2 in Bactron Anaerobic Chamber, 
BACLITE- 2 (Sheldon Manufacturing, Cornelius, OR).
HIF- 1 inhibitor YC- 1 (Cayman Chemical Company, Ann 
Arbor, MI) was dissolved in dimethyl sulfoxide at a con-
centration of 20 mg/mL to prepare a stock solution. 
Vinorelbine was purchased from WAKO (Osaka, Japan).
Plasmids­and­transfection
A549 cells were trypsinized, counted, and seeded 1 day 
before transfection to achieve 70% confluency on the day 
of making lysates.
Small- interfering RNAs (siRNAs) targeting HIF-1α were 
purchased from Invitrogen (Waltham, MA), and siRNAs 
targeting CAIX and control siRNAs were purchased from 
Japan Bio Services Co., LTD (Saitama, Japan). A549 cells 
were transfected with the specific siRNAs (final concen-
tration, 120 nmol/L) by using RNAiMAX (Invitrogen), 
according to the manufacturer’s instructions. Targeting 








(3) Nonspecific control siRNAs (negative control) 
   5ʹ-GCGCGCUUUGUAGGAUUCG-3ʹ
The plasmid expressing a short hairpin RNA (shRNA) 
targeting HIF-1α was purchased from Qiagen (Hilden, 
Germany), and stably transfected into A549 cells through 
the calcium phosphate method [10]. The resultant cells 
were cultured in selection medium containing puromycin 
(1 μg/mL) for 14 days to establish HIF-1α- silencing A549 
cells.
To construct pcDNA4/HIF- 1α 3A, which expresses a 
constitutively active mutant HIF- 1α, pcDNA4/HIF- 1α 
plasmid was introduced with three- point mutations, P402A, 
P564A, and N803A (HIF- 1α 3A herein), through the site- 
directed mutagenesis. The mutations in proline and aspara-
gine residues enable HIF- 1α protein to avoid the prolyl 
4- hydroxylases (PHDs)- mediated proteolysis and the factor- 
inhibiting HIF- 1- dependent suppression of transactivation 
activity of HIF- 1α, respectively [11]. Cells were transfected 
with this recombinant vector or control vector by using 
Lipofectamine 2000 (Invitrogen), according to the manu-
facturer’s instructions.
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Western­blotting
A549 cells were seeded 1 day before treatment to ensure 
70% cell confluency on the day of making lysates. The 
cells were treated with the reagents or the vectors for 
24 h. Cell lysates were harvested by lysing the cells in 
4- (2- hydroxyethyl)- 1- piperazineethanesulfonic acid buffer 
containing protease inhibitors (1 mmol/L phenylmethyl-
sulfonyl fluoride, 1 μg/mL aprotinin, 1 μg/mL pepstatin, 
0.5 μg/mL leupeptin, and 1 mmol/L vanadate). The lysates 
were immunoblotted using antibodies against HIF- 1α 
(610958, BD Bioscience, San Jose, CA), GLUT1 (ab40084, 
Abcam, Cambridge, UK), CAIX (M75, Bioscience Slovakia, 
Bratislava, Slovakia), and β- actin (A5441, Sigma- Aldrich), 
which was used as a control. For hypoxic experiments, 
cell lysates were harvested in a hypoxic chamber and were 
treated as described above.
Cell­proliferation­assay
A549 cells were seeded in 96- multiwell plates (3000 cells/
well) containing DMEM supplemented with 10% FBS 
and were incubated overnight. The cells were then treated 
with vinorelbine and were incubated under normoxia 
or hypoxia for 72 h. Cell proliferation rate was measured 
using 4- [3- (4- iodophenyl)- 2- (4- nitrophenyl)- 2H- 5- tetraz
olio]- 1,3- benzenedisulfonate (WST- 1) colorimetric assay 
(Dojindo, Kumamoto, Japan), according to the manu-
facturer’s instructions. All measurements were performed 
in triplicate.
Metabolic­flux­assay
Bioenergetic flux of HIF- 1α- overexpressing cells under 
normoxia was assessed using Seahorse XF96 extracellular 
flux analyzer (Seahorse Biosciences, North Billerica, MA). 
For this, A549 cells, which were transfected with the vec-
tor expressing the constitutively active mutant HIF- 1α or 
control vector for 24 h, were seeded in XF96 plates at 
50,000 cells/well (after optimization of cell seeding number) 
and were incubated with DMEM in 5% CO2 at 37°C for 
24 h. Cell culture medium was replaced with XF medium 
(Seahorse Biosciences) containing 10% glutamine and 
lacking sodium bicarbonate and FBS. The cells were then 
incubated in the absence of CO2 at 37°C for 1 h before 
initiating the experiment. Basal extracellular acidification 
rate (ECAR), which indicates proton leakage during gly-
colysis, and basal oxygen consumption rate (OCR), which 
indicates mitochondrial respiration, were measured using 
XF96 plate reader according to the manufacture’s instruc-
tion. OCR and ECAR values were normalized using cell 
counts (ECAR: mpH/[min · 104 cells], OCR: pmol/
[min · 104 cells]).
Immunohistochemical­analysis
Immunohistochemical analysis of HIF- 1α, GLUT1, and 
CAIX was performed using a standard technique published 
previously [12]. Briefly, HIF- 1α, GLUT1, and CAIX were 
immunostained using rabbit anti- human HIF- 1α polyclonal 
antibody (dilution, 1:500; Novus, Littleton, CO), mouse 
anti- human GLUT1 monoclonal antibody (ab40084; dilu-
tion, 1:200), and mouse anti- human CAIX monoclonal 
antibody (M75, 1:100), respectively. Next, ABC method 
was performed using Vectastain ABC kit (Tokyo, Japan), 
according to the manufacturer’s instructions.
Immunostained sections were examined by two authors 
(T. S. and T. M.) who were blinded to patient charac-
teristics. Cases showing discrepancies were jointly reevalu-
ated until consensus was reached. HIF- 1α, GLUT1, and 
CAIX expression was examined in four distinct fields 
containing a minimum of 500 cells. The proportion of 
positive cells was measured and classified as 0 (no stain-
ing), +1 (weak), +2 (moderate), and +3 (strong), and 
each specimen was categorized as negative (0 and +1) or 
positive (+2 and +3). Representative images of immuno-
histochemical staining are shown in Figure 4A.
For this analysis, in all 25 NSCLC specimens were col-
lected from stage IIIA advanced NSCLC patients with patho-
logically proven mediastinal lymph node metastasis (N2) who 
received induction chemoradiotherapy at Kyoto University 
Hospital from 2006 to 2014. These patients were treated by 
platinum- doublet chemotherapy (carboplatin and paclitaxel 
or cisplatin and vinorelbine) with concurrent radiotherapy. 
Tumors were staged using the 7th Edition of the TNM 
classification of the International Union Against Cancer [13]. 
Survival time and outcome data were available for all the 
25 patients. Median follow- up duration of the 25 patients 
was 45 months (range: 14–111 months). Use of the patient 
specimens in this study was approved by the Institutional 
Review Board of the Kyoto University Hospital. Written 
informed consent was obtained from all of the patients.
Statistical­analysis
Differences in ECAR and OCR values were statistically 
analyzed using t- test. Time- to- event curves for overall sur-
vival (OS) and disease- free survival (DFS) were estimated 
using Kaplan–Meier method, and differences in these curves 
were calculated using log- rank test. Correlations among 
the expression of HIF- 1α, GLUT1, and CAIX in the clini-
cal specimens were analyzed using chi- square test. All P- 
values were two sided, and P < 0.05 was considered 
statistically significant. These analyses were performed using 
JMP Pro 11 (SAS, Cary, NC). Best- fit IC50 values were 
compared using an extra sum- of- square F test with Prism 
6 (GraphPad Software Inc., San Diego, CA).
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Results
In­vitro­study
Hypoxia induced HIF- 1α, GLUT1, and CAIX 
expression in lung cancer cells
First, we studied the behavior of HIF- 1α, GLUT1, and 
CAIX in the lung cancer cell- line A549 under normoxia 
and hypoxia.
A549 cells were incubated under normoxia or hypoxia 
for 24 h, and expression of HIF- 1α, GLUT1, and CAIX 
in cell lysates was determined by performing Western 
blotting. It was shown that HIF- 1α, GLUT1, and CAIX 
expression was stronger under hypoxia than under nor-
moxia (Fig. 1A). Our results showed that hypoxia induced 
the expression of GLUT1, which is associated with the 
intake of glucose into cells, and CAIX, which neutralizes 
glycolysis- associated intracellular acidosis, in A549 cells.
Hypoxia induced GLUT1 and CAIX expression in 
lung cancer cells in a HIF- 1- dependent manner
Because our results showed that hypoxia induced GLUT1 
and CAIX expression in A549 cells, we investigated whether 
this expression was induced in a HIF- 1- dependent 
manner.
HIF- 1 inhibitor YC- 1 was used to inhibit HIF- 1α in 
A549 cells. A549 cells were seeded and incubated with 
YC- 1 (20, 60, and 120 μmol/L) for 24 h. Results of Western 
blotting showed that inhibition of HIF- 1 with YC- 1 sup-
pressed GLUT1 and CAIX expression in a dose- dependent 
manner (Fig. 1B). The involvement of HIF- 1 was further 
confirmed by treating A549 cells with HIF-1α siRNAs for 
24 h. Our results showed that GLUT1 and CAIX expres-
sion was suppressed in HIF-1α- knockdown A549 cells 
(Fig. 1C).
These results indicated that hypoxia induced GLUT1 
and CAIX expression in a HIF- 1- dependent manner and 
that HIF- 1 was a key regulator of GLUT1 and CAIX 
expression in lung cancer cells.
HIF- 1 induced glycolysis in lung cancer cells
Above results suggested a possibility that HIF- 1- dependent 
induction of GLUT1 expression led to the increase in 
glucose consumption. However, it was unclear whether 
upregulation of GLUT1 expression and increase in glucose 
consumption were induced by glycolysis rather than by 
oxidative phosphorylation.
Therefore, we used the extracellular flux analyzer to 
investigate whether HIF- 1 induced glycolysis. We measured 
basal ECAR, an index of glycolysis, and basal OCR, an 
index of oxidative phosphorylation, in A549 cells with or 
without genetical activation of HIF- 1α under normoxia. 
Because experiments involving the extracellular flux analyzer 
are performed under normoxia, we overexpressed HIF- 1α 
in A549 cells under normoxia by transfecting these cells 
with the vector encoding the constitutively active mutant 
HIF- 1α with three mutations, P402A, P564A, and N803A 
(HIF- 1α 3A). The use of this mutant allowed the evalu-
ation of direct effects of HIF- 1α even under normoxia.
Western blotting detected HIF- 1α overexpression in A549 
cells transfected with the vector encoding the constitutively 
active mutant HIF- 1α (Fig. 2A), hereinafter referred to as 
Figure 1. Hypoxia induced HIF- 1α, GLUT1, and CAIX expression in A549 cells. Moreover, hypoxia induced GLUT1 and CAIX expression in a 
HIF- 1- dependent manner. (A) HIF- 1α, GLUT1, and CAIX expression in A549 cells was stronger under hypoxia than under normoxia. (B) HIF- 1 
inhibitor YC- 1 suppressed HIF- 1α, GLUT1, and CAIX expression under hypoxia in a dose- dependent manner. (C) HIF-1α siRNAs suppressed 
GLUT1 and CAIX expression under hypoxia. It indicated that hypoxia induced GLUT1 and CAIX expression in A549 cells in a HIF- 1- dependent 
manner. HIF- 1α, hypoxia- inducible factor 1α; GLUT1, glucose transporter 1; CAIX, carbonic anhydrase IX. 
A B C
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Figure 2. HIF- 1 induced glycolysis in A549 cells. (A) Western blotting detected HIF- 1α overexpression in A549 cells transfected with the vector 
encoding the constitutively active mutant HIF- 1α. (B) Under normoxia, ECAR increased by 133% and OCR decreased by 23.7% in HIF- 1α 3A- 
overexpressing A549 cells compared with that in control cells (t- test, **P < 0.001). OCR and ECAR values were standardized using cell counts. 
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HIF- 1α 3A- overexpressing A549 cells. Experiment using 
the extracellular flux analyzer showed that the ECAR 
increased significantly (by 133%) and OCR decreased sig-
nificantly (by 23.7%) in HIF- 1α 3A- overexpressing A549 
cells compared with that in control cells (Fig. 2B).
These results indicated that HIF- 1 shifted glucose meta-
bolic pathway from oxidative phosphorylation to glycolysis 
in A549 cells.
HIF- 1 induced chemoresistance of lung cancer cells 
to vinorelbine
Our results showed that HIF- 1 induced glycolysis and 
CAIX expression in A549 cells. Therefore, we examined 
the effects of HIF- 1α expression on chemoresistance of 
lung cancer. Cytotoxicity was measured by performing 
WST- 1 assay with or without HIF- 1α overexpression under 
normoxia. HIF- 1α overexpression was induced using the 
vector encoding the constitutively active mutant HIF- 1α 
(Fig. 2A). Under normoxia, the HIF- 1α 3A- overexpressing 
A549 cells showed significant chemoresistance to vinorel-
bine (Fig. 3A), suggesting that HIF- 1 induced chemore-
sistance of lung cancer.
HIF- 1 inhibition under hypoxia restored the 
chemosensitivity of lung cancer cells to 
vinorelbine
Next, we investigated whether HIF- 1 inhibition restored 
the chemosensitivity of A549 cells to vinorelbine under 
hypoxia. For this, we established stable HIF-1α- knockdown 
A549 cells by silencing HIF-1α expression with a shRNA 
expression vector (Fig. 3B). We compared the chemore-
sistance of HIF-1α- knockdown and control A549 cells to 
vinorelbine by WST- 1 assay.
Our results showed that HIF-1α- knockdown A549 cells 
were significantly more chemosensitive to vinorelbine than 
control cells under hypoxia (Fig. 3C), suggesting that 
HIF- 1 inhibition restored the chemosensitivity of A549 
cells to vinorelbine under hypoxia.
CAIX inhibition under hypoxia restored the 
chemosensitivity of lung cancer cells to 
vinorelbine
In our study, we found that HIF- 1 induced glycolysis, 
CAIX expression, and chemoresistance in A549 cells. 
Therefore, we hypothesized that HIF- 1- induced chem-
oresistance was mediated by CAIX expression. We inves-
tigated whether CAIX inhibition under hypoxia affected 
the chemosensitivity of A549 cells. Cytotoxic effects of 
vinorelbine on CAIX- knockdown A549 cells, which were 
obtained by transfecting A549 cells with CAIX siRNAs 
(Fig. 3D), under hypoxia was measured by performing 
the WST- 1 assay.
Our results showed that CAIX- knockdown cells were sig-
nificantly more chemosensitive to vinorelbine than control 
cells under hypoxia (Fig. 3E), suggesting that CAIX inhibition 
under hypoxia restored the chemosensitivity of A549 cells.
Clinical­study
Clinical significance of HIF- 1α and other hypoxia- 
associated metabolic factors in prognosis of NSCLC 
patients after induction chemoradiotherapy
We investigated the effects of hypoxia- associated factors 
on prognosis of NSCLC patients after induction chemo-
radiotherapy and surgery. For this, resected specimens 
from 25 patients of stage IIIA NSCLC who received induc-
tion chemoradiotherapy were collected at Kyoto University 
Hospital from 2006 to 2014. HIF- 1α, GLUT1, and CAIX 
expression in the collected specimens were examined by 
performing immunohistochemical analyses (Fig. 4A). 
Associations between the expression of these factors and 
patient prognosis were statistically analyzed. 
Clinicopathological characteristics of the patients evaluated 
in our study are summarized in Table 1.
Results of Kaplan–Meier method and log- rank test 
showed that HIF- 1α, GLUT1, and CAIX expression was 
significantly associated with poor OS and DFS of NSCLC 
patients who received induction chemoradiotherapy (OS: 
HIF- 1α, P = 0.037; GLUT1, P = 0.005; CAIX, P < 0.001; 
DFS: HIF- 1α, P = 0.048; GLUT1, P = 0.005; CAIX, 
P = 0.025) (Fig. 4B). Mutual associations were significantly 
observed between the expression of HIF- 1α and GLUT1 
and between the expression of GLUT1 and CAIX. (Chi- 
squared test: HIF- 1α- GLUT1, P = 0.002; GLUT1- CAIX, 
P = 0.016) but not between the expression of HIF- 1α 
and CAIX (P = 0.061) (Fig. 4C). These results indicated 
that expression of HIF- 1α, GLUT1, and CAIX was cor-
related with poor prognosis of NSCLC patients after 
induction chemoradiotherapy.
Discussion
In this study, we found that HIF- 1 and its associated 
factor CAIX induced chemoresistance of A549 cells and 
that these factors were associated with prognosis of stage 
IIIA advanced NSCLC patients after induction chemora-
diotherapy. To our knowledge, this is the first study to 
report these results for lung cancer. Moreover, these results 
may help in developing novel strategies for treating 
advanced lung cancer.
Previous studies have reported that HIF- 1 plays impor-
tant roles in cancer progression and metastasis [4]. Activity 
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of HIF- 1 is mainly regulated in an oxygen- dependent 
manner. PHDs hydroxylates the proline residues in the 
oxygen- dependent degradation domain of HIF- 1α under 
normoxia. This hydroxylation triggers the ubiquitination 
of HIF- 1α by VHL- containing E3 ubiquitin ligase, leading 
to its proteolysis [14, 15]. HIF- 1 activity is mainly 
regulated by HIF- 1α in an oxygen- dependent manner, 
and it indicates that HIF- 1α is one of the most important 
factors induced under hypoxia.
HIF- 1α has been reported to promote cancer progres-
sion through multiple mechanisms [4]. Moreover, clinical 
studies have shown that HIF- 1α promotes cancer metastasis 
Figure 3. HIF- 1 and CAIX affected the chemosensitivity of A549 cells under hypoxia. (A) Under normoxia, HIF- 1α 3A- overexpressing A549 cells 
showed significant chemoresistance to vinorelbine in WST- 1 assay. (B) Stable HIF-1α- knockdown A549 cells, which were obtained by treatment with 
HIF-1α shRNA vector, showed suppressed HIF- 1α expression compared with control cells. (C) Under hypoxia, HIF-1α- knockdown A549 cells showed 
more chemosensitivity to vinorelbine than control cells in WST- 1 assay. (D) CAIX- knockdown A549 cells, which were transfected with CAIX siRNAs, 
showed suppressed CAIX expression compared with control cells. (E) Under hypoxia, CAIX- knockdown cells showed more chemosensitivity to 
vinorelbine than control cells in WET- 1 assay. Best- fit IC50 values were compared using the extra sum- of- square F test by using Prism 6 (**P < 0.001). 
Each value was standardized using that obtained for control cells. HIF- 1, hypoxia- inducible factor 1; CAIX, carbonic anhydrase IX; WST1, 4- [3- (4- 
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and relapse [16]. Our previous study showed that HIF- 1α 
and ubiquitin C- terminal hydrolase- L1 were correlated with 
cancer metastasis and were associated with prognosis of 
patients with lung adenocarcinoma [11]. In our study, we 
could provide new insights on HIF- 1α in lung cancer.
Although various mechanisms underlying the effect of 
HIF- 1 on cancer progression have been reported, clinical 
application of HIF- 1 inhibitors for inhibiting cancer pro-
gression has not been performed to date [17]. HIF- 1 exists 
in the nuclei of cancer cells; therefore, HIF- 1 inhibitors 
may not be able to reach it. In contrast, CAIX is a cell 
surface protein that can be easily accessed for treatment 
and is almost exclusively expressed on cancer cells but 
not on surrounding normal cells, except gastric cells. This 
is one of the reasons why we focused on CAIX in our 
study.
CAIX, an intracellular pH regulator that induces tissue 
growth and development, is associated with hypoxia and 
glycolysis. CAIX neutralizes intracellular acidosis induced 
by glycolysis- associated lactate and proton along with a 
bicarbonate transporter [8, 18]. In our study, we found 
that CAIX induced chemoresistance of A549 cells. Although 
Figure 4. Analysis of the associations between HIF- 1α, GLUT1, and CAIX expression and prognosis of NSCLC patients after induction 
chemoradiotherapy. (A) Representative images of the immunohistochemical staining of NSCLC sections with anti- HIF- 1α (a and b), GLUT1 (c and d), 
and CAIX (e and f) antibodies. (a, c, and e) show positive expression, whereas (b, d, and f) show negative expression. (Scale bar, 50 μm, Original 
magnification, 400×.) (B) Results of Kaplan–Meier method and log- rank test showed that HIF- 1α, GLUT1, and CAIX expression was significantly 
associated with poor OS and DFS of NSCLC patients who received induction chemoradiotherapy (OS: HIF- 1α, P = 0.037; GLUT1, P = 0.005; CAIX, 
P < 0.001; DFS: HIF- 1α, P = 0.048; GLUT1, P = 0.005; CAIX, P = 0.025). *P < 0.05, **P < 0.01. (C) Mutual association was observed between the 
expression of HIF- 1 and GLUT1 and between the expression of GLUT1 and CAIX (Chi- squared test: HIF- 1α–GLUT1, P = 0.002; GLUT1–CAIX, 
P = 0.016), but not between the expression of HIF- 1α and CAIX (P = 0.061). *P < 0.05, **P < 0.01. HIF- 1α, hypoxia- inducible factor 1α; GLUT1, 
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we did not prove a causal relationship between CAIX 
expression and chemoresistance, the two mechanisms were 
mainly reported [9, 18–20]. First, chemotherapy induces 
intracellular acidosis, and CAIX prevents apoptosis by 
maintaining a normal intracellular pH in response to 
chemotherapy [9]. Second, CAIX- induced extracellular 
acidosis is responsible for chemoresistance of cancer cells. 
CAIX converts CO2 and H2O into H
+ and HCO3
− in the 
extracellular space, which induces intracellular alkalosis 
through bicarbonate transporter and H+- induced extracel-
lular acidosis in the extracellular space. Most anticancer 
drugs, including vinorelbine, are charged weak bases and 
become protonated and impaired at acidic extracellular 
pH [18–20]. Thus, CAIX inhibition may suppress chem-
oresistance of cancer cells through these two 
mechanisms.
Our clinical analysis showed that HIF- 1α and CAIX 
were associated with prognosis of NSCLC patients after 
induction chemoradiotherapy. Although some studies have 
reported the importance of CAIX in prognosis of lung 
cancer patients [21], the exact mechanism remains unclear. 
On the other hand, our analysis of 239 resected lung 
adenocarcinoma specimens at our institute did not show 
the association of CAIX expression with patient prognosis 
(data not shown) [22]. These results may provide new 
insights on using CAIX as a target for treating advanced 
lung cancer requiring induction chemoradiotherapy. 
Furthermore, clinical trials on novel inhibitors of CAIX 
are in progress [8, 23], and results of these trials are 
expected to improve patient prognosis. Thus, our study 
suggested that cancer therapy involving CAIX inhibition 
would provide promising results.
However, our study has limitations. First, data of only 
25 patients with stage IIIA advanced NSCLC were included 
in our study. We selected the cases from a homogeneous 
group of patients limited to stage IIIA advanced NSCLC 
with pathologically proven mediastinal lymph node metas-
tasis, for the sake of the accurate analysis. Future studies 
should be performed using data from more number of 
patients. Second, our results showed the association between 
HIF- 1- associated factors and prognosis of lung cancer 
patients. However, they did not indicate whether these 
factors were predictors of the effectiveness of preoperative 
induction chemoradiotherapy. For the further investiga-
tion, 18F- Fluoromisonidazole (FMISO) positron emission 
tomography is now in clinical trial in Kyoto University. 
FMISO accumulates in hypoxic regions of cancer tissues 
and allows their visualization [24], and it will determine 
whether hypoxic regions exist in lung cancer before the 
initiation of induction chemoradiotherapy and whether 
these regions can predict the effectiveness of induction 
chemoradiotherapy. It will also be useful for developing 
clinical therapies involving HIF- 1 and CAIX inhibitors, 
especially for treating NSCLC patients after induction 
chemoradiotherapy.
Conclusion
Our results showed that HIF- 1 induced glycolysis and 
the expression of CAIX, which affected the chemosensitiv-
ity and prognosis of lung cancer patients. HIF- 1 and CAIX 
inhibition may improve patient prognosis, especially prog-
nosis of stage IIIA NSCLC patients after induction chemo-
radiotherapy. Further studies on the novel applications 
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